Zevra Therapeutics Inc
ZVRA11.250USD
+0.140+1.26%
收盘 08/04, 16:00（美东）报价延迟15分钟
615.14M总市值
亏损市盈率 TTM
关于 Zevra Therapeutics Inc 公司
Zevra Therapeutics, Inc. 是一家罕见病公司，致力于为治疗选择有限或没有治疗选择的疾病创造转化疗法，以满足科学、数据和患者的需求。该公司拥有多元化的产品和候选产品组合，包括临床阶段产品线和商业阶段资产的组合。其产品线包括 arimoclomol，这是一种口服的试验性候选产品，正在开发用于治疗尼曼匹克病 C 型 (NPC)。KP1077 是该公司的主要临床开发候选产品，正在开发用于治疗特发性嗜睡症 (IH)，这是一种罕见的神经性睡眠障碍和发作性睡病。其商业产品 AZSTARYS 是一种每日一次的注意力缺陷多动障碍 (ADHD) 治疗药物，适用于 6 岁及以上的患者，包含其前体药物 serdexmethylphenidate (SDX) 和 d-methylphenidate (d-MPH)。其另一种商业产品是 OLPRUVA。
公司简介
公司代码ZVRA
公司名称Zevra Therapeutics Inc
上市日期Apr 16, 2015
CEOMr. Neil F. Mcfarlane
员工数量59
证券类型Ordinary Share
年结日Apr 16
公司地址1180 Celebration Boulevard
城市CELEBRATION
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编34747
电话13219393416
网址https://zevra.com/
公司代码ZVRA
上市日期Apr 16, 2015
CEOMr. Neil F. Mcfarlane
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Dr. Adrian Quartel, M.D.
Dr. Adrian Quartel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Corey Watton
Mr. Corey Watton
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
收入明细
FY2024
FY2023
FY2022
FY2021
FY2020
暂无数据
地区USD
名称
营收
占比
United States
23.61M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
持股股东
持股股东
占比
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
股东类型
持股股东
占比
Hedge Fund
24.22%
Investment Advisor
22.55%
Investment Advisor/Hedge Fund
14.58%
Research Firm
1.43%
Private Equity
1.25%
Individual Investor
0.71%
Venture Capital
0.33%
Bank and Trust
0.11%
Pension Fund
0.06%
Other
34.76%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
239
35.69M
65.27%
-2.27M
2025Q1
252
39.54M
72.42%
-1.74M
2024Q4
247
37.53M
70.32%
+3.07M
2024Q3
232
32.67M
61.46%
+11.34M
2024Q2
214
19.77M
45.38%
+395.88K
2024Q1
213
17.66M
40.45%
-265.50K
2023Q4
207
16.32M
37.86%
+175.17K
2023Q3
203
14.77M
38.14%
-620.11K
2023Q2
208
12.57M
36.97%
-1.13M
2023Q1
207
10.52M
30.95%
-2.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Woodline Partners LP
4.62M
8.44%
+476.03K
+11.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.78M
6.92%
+18.09K
+0.48%
Mar 31, 2025
Adage Capital Management, L.P.
3.62M
6.62%
-32.00K
-0.88%
Mar 31, 2025
The Vanguard Group, Inc.
2.83M
5.17%
+1.63K
+0.06%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.19M
4%
-15.70K
-0.71%
Mar 31, 2025
Nantahala Capital Management, LLC
1.47M
2.69%
-868.40K
-37.11%
Mar 31, 2025
Altium Capital Management LP
1.29M
2.35%
-562.67K
-30.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.23M
2.26%
+44.99K
+3.79%
Mar 31, 2025
683 Capital Management LLC
1.23M
2.24%
--
--
Mar 31, 2025
Rubric Capital Management LP
1.22M
2.23%
+601.61K
+97.64%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Simplify Propel Opportunities ETF
1.92%
iShares Neuroscience and Healthcare ETF
1.17%
SPDR S&P Pharmaceuticals ETF
0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.35%
iShares Micro-Cap ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Simplify Propel Opportunities ETF
占比1.92%
iShares Neuroscience and Healthcare ETF
占比1.17%
SPDR S&P Pharmaceuticals ETF
占比0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.35%
iShares Micro-Cap ETF
占比0.11%
Invesco Nasdaq Biotechnology ETF
占比0.05%
iShares Biotechnology ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Vanguard US Momentum Factor ETF
占比0.04%
iShares Russell 2000 Growth ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
